BAYER AG NA
Commented by Armin Schulz on April 4th, 2025 | 07:10 CEST
Bayer's cancer drugs, Defence Therapeutics' cancer vaccine, Novo Nordisk's fat burner – Back on the road to success through specialization
The new trade tariffs threaten to destabilize the global supply chains of the pharmaceutical industry, increase the prices of generic drugs, and slow innovation cycles. The only winners in this environment will be those who focus on unique innovations to ensure resilience and growth. Bayer is trying to make itself fit for the future with an efficiency program, new pharmaceutical products, and digital agriculture platforms. Defence Therapeutics excels with precision-medicine cancer vaccines based on patented technology, opening up new markets. Novo Nordisk, in turn, is shaping a multibillion-dollar market with GLP-1 therapies for obesity and diabetes based on closed production cycles. These three approaches show how specialization and adaptability open new paths in turbulent times.
Read
Commented by André Will-Laudien on April 1st, 2025 | 07:20 CEST
Was that the Trump crash? Nevertheless, steeply upwards with Evotec, Bayer, BioNTech, Defence Therapeutics, or Valneva?
Since November 2024, Donald Trump has driven the markets sharply upward - his controversial new presidency was largely celebrated by investors. Now, his leadership feels somewhat unsettling, with fires seemingly being set again at every corner. The new president is acting more imperiously than ever, with Panama, Canada, and Greenland verbally on the agenda as the next US states. Meanwhile, the US administration is facing a considerable deficit, which is to be addressed by drastically reducing the size of the public sector and introducing tariffs. Unsurprisingly, interest rates are now rising sharply, which is a reason for weaker prices in the biotech sector. However, the sector has done its homework and is emerging from a three-year downturn. Are we now at buying levels?
Read
Commented by Fabian Lorenz on March 25th, 2025 | 07:00 CET
Takeover speculation and buy recommendations: Buy Bayer, BioNTech, and BioNxt Solutions stock after a 150% rally?
While takeover speculations are currently on pause for Evotec, they are gaining momentum for BioNxt Solutions. The Company aims to achieve significant milestones in the next 60 days on the road to marketing its lead product for treating multiple sclerosis and expanding into the billion-dollar anti-aging market. Even after the 150% rally, BioNxt shares are not expensive. The BioNTech share has corrected sharply in 2025. However, positive analyst comments could now herald a turnaround. Will the oncology pipeline lead to a breakthrough? On the other hand, Bayer is facing a significant defeat in USD. Further billion-dollar payments are looming. Analysts remain skeptical.
Read
Commented by Stefan Feulner on March 24th, 2025 | 07:20 CET
Bayer, Vidac Pharma, BioNTech – Setbacks and New Standards
Glyphosate and no end in sight. Bayer's 2018 acquisition of US agricultural company Monsanto continues to develop into a billion-dollar grave, with a court again ruling against the Leverkusen-based company. Billions in revenue also disappeared from the books of vaccine manufacturer BioNTech after the COVID-19 pandemic subsided. In contrast, an innovative biopharmaceutical company is setting new standards in treating pediatric brain tumors.
Read
Commented by Armin Schulz on March 18th, 2025 | 07:00 CET
Bayer, Vidac Pharma, BioNTech – Making money with biotech and pharmaceutical innovations
More and more investors are betting on companies that are leaving traditional therapeutic paths to rethink cancer, chronic inflammation, or nutritional issues. While some corporations struggle with their balance sheets due to mountains of debt and patent expirations, others are quietly developing technologies that crack the metabolic code of diseases. Whether anti-aging tests from saliva samples, mRNA-based cancer cocktails, or active ingredients that overcome the blood-brain barrier – the stock market rewards those who combine research success with strategic risk-taking. But which companies have what it takes to develop the blockbusters of tomorrow? Let's take a closer look at three companies.
Read
Commented by Stefan Feulner on March 11th, 2025 | 07:30 CET
Bayer, BioNxt Solutions, Novo Nordisk – The pressure is on
The biotech sector has started the new year with momentum, and the acquisition wave is heating up, as confirmed by Johnson & Johnson's acquisition of Intra-Cellular Therapies for USD 15 billion. The trend will likely continue as major pharmaceutical companies are under massive pressure to strengthen their portfolios. After all, drug patents worth over USD 200 billion will expire by the end of the decade. This will force the giants to make strategic acquisitions.
Read
Commented by André Will-Laudien on March 3rd, 2025 | 07:35 CET
Biotech: Takeover candidates for 2025! Things are heating up at Evotec, BioNxt, Bayer, and Formycon!
The DAX 40 index is hitting new highs, following a gigantic wave of buying from the US. The rally is already well advanced, but due to ongoing geopolitical upheavals, high-tech and defense stocks are still performing well. In recent weeks, the positive trends have also spread to the biotech sector again. Stocks such as BioNxt have already gained over 150% in the last six months. What is driving this? Formycon has seen a severe price drop, while Bayer and Evotec are slowly getting back on track. Are we going to see takeovers now? What are the triggers for dynamic investors?
Read
Commented by Armin Schulz on February 27th, 2025 | 07:30 CET
Bayer, BioNxt Solutions, Evotec – Artificial intelligence as a gamechanger in pharmaceutical research
New technologies and innovative solutions will completely transform the future of medicine. To prepare for this as well as possible, hurdles such as bureaucracy, financial issues, and outdated structures must be overcome. At the same time, management must set the course, as development is continuing at a rapid pace – whether through artificial intelligence (AI) in drug research or customized therapies for individual patients. One thing is clear: anyone who wants to keep up here must think differently. But how are companies tackling this in practice? Three examples reveal why flexibility and fresh ideas are crucial right now for staying ahead in the long term.
Read
Commented by Armin Schulz on February 19th, 2025 | 07:10 CET
Bayer, Vidac Pharma, Pfizer – Dementia, cancer, obesity: The race for the billion-dollar markets
The pharmaceutical industry is in the throes of a major upheaval – it is no longer just about research but also about big money. Whoever is ahead now secures not only fame but, above all, extremely lucrative markets. Looking at how companies are currently driving forward mergers or acquiring startups, it is clear: The battle for the next blockbuster drugs has long since become a billion-dollar gamble. There is a lot of activity, especially in areas such as cancer, dementia, and obesity. Everyone wants to be the first to patent the golden active ingredient. We take a look at three companies that are researching the next blockbusters.
Read
Commented by Fabian Lorenz on February 12th, 2025 | 07:00 CET
Analysts on the TUI CRASH! Bayer to make millions! dynaCERT stock is set to skyrocket!
Will the dynaCERT stock see a breakthrough soon? The odds are looking good. In an analyst interview, the top German manager cites an increase in revenue, sales, and earnings as a clear goal for the next 12 months. In that case, the stock would currently be a bargain. The TUI share, however, does not appear to be a bargain for investors. The quarterly figures led to a sell-off yesterday. Yet revenue and earnings were in line with expectations. What do analysts say? Bayer's stock also trended weak yesterday, despite new potential millions in revenue from a drug approval.
Read